Chi-Med initiates HMPL-523 clinical trials

Hutchison China MediTech Limited has initiated a phase I trial of its novel spleen tyrosine kinase (Syk) inhibitor, HMPL-523, in patients with hematological malignancies in China.

The first patient was dosed on 27 December.

This study complements the ongoing Phase I trial in patients in Australia with haematological malignancies, which is expected to complete dose-escalation in the first half of 2017.

Story provided by